Nishibe Y, Matsuo Y, Yoshizaki T, Eigyo M, Shiomi T, Hirose K
Naunyn Schmiedebergs Arch Pharmacol. 1982 Dec;321(3):190-4. doi: 10.1007/BF00505484.
Sulpiride (SUL) is more efficacious in antipsychotic activity than metoclopramide (MET), although both appear to possess almost equal affinities for dopamine (DA) receptors. We studied the effects of SUL and MET on the brain homovanillic acid (HVA) level and shuttle box avoidance to clarify their differential modes of action on the blockade of DA receptors. SUL was several times less potent than MET, which was about 50 times less potent than the control drug haloperidol (HAL), for increasing HVA at 4 h after s.c. administration. However, SUL was about 50 times more potent than MET and about equipotent to HAL, at 2 h after drug administration into the lateral ventricle. The potency of SUL by intraventricular administration was 20-fold or more than that by intracisternal administration. HAL and MET did not show such a discrepancy. The HVA level reached the maximum 1 h after intraventricular administration of MET or HAL, while s.c., intracisternal or intraventricular administration of SUL caused a gradual increase in the HVA level with the maximum being reached after 6-8 h. In shuttle box avoidance, MET was about 25 times more potent than SUL by intraperitoneal administration but about 200 times less potent than SUL, which was about 10 times more potent than HAL, by intraventricular administration. These results suggest that SUL causes a potent, long-lasting blockade of DA receptors, while MET has only a weak, short-lasting action. These findings may be related to the differences in their clinical efficacy.
舒必利(SUL)在抗精神病活性方面比甲氧氯普胺(MET)更有效,尽管两者对多巴胺(DA)受体的亲和力似乎几乎相等。我们研究了SUL和MET对脑内高香草酸(HVA)水平和穿梭箱回避反应的影响,以阐明它们在阻断DA受体方面的不同作用方式。皮下注射后4小时,SUL升高HVA的效力比MET低几倍,而MET的效力比对照药物氟哌啶醇(HAL)低约50倍。然而,在侧脑室给药后2小时,SUL的效力比MET高约50倍,与HAL相当。脑室注射SUL的效力比脑池内注射高20倍或更多。HAL和MET没有显示出这种差异。MET或HAL脑室注射后1小时HVA水平达到最大值,而SUL皮下、脑池内或脑室注射导致HVA水平逐渐升高,6 - 8小时后达到最大值。在穿梭箱回避试验中,腹腔注射时MET的效力比SUL高约25倍,但脑室注射时MET的效力比SUL低约200倍,SUL的效力比HAL高约10倍。这些结果表明,SUL能强效、持久地阻断DA受体,而MET只有微弱、短暂的作用。这些发现可能与它们临床疗效的差异有关。